title: Effects of olmesartan therapy on the expression of lung adrenoceptors in rats with chronic heart failure.
abstract: BACKGROUND
  Adrenergic receptors (AR) play important roles in regulating lung function. However, there are few reports concerning AR expression and the protective effect of angiotensin II receptor blockers (ARB) on the lung in chronic heart failure (CHF). In this study, we aimed to investigate the protective effects of the ARB olmesartan on the lung in CHF.
  
  
  METHODS
  Wistar rats were randomly divided into four groups: normal control, sham-operated rats, rats with CHF induced by ligating the left anterior descending coronary arteries, and rats with CHF treated with olmesartan (1 mg/kg) once daily for 8 weeks. Heart function, plasma renin activity (PRA) and angiotensin II (Ang II) levels, lung microscopic structure inspection and mRNA and protein expressions of α1A-, β1- and β2-AR in lung were tested.
  
  
  RESULTS
  Compared with the CHF group, PRA and Ang II levels were decreased while heart function and mRNA and protein expression of α1A-AR, β1-AR and β2-AR were up-regulated in the olmesartan group (p<0.05 or p<0.01). The inflammation and cell proliferation in CHF lung tissue were reduced in the olmesartan group.
  
  
  CONCLUSIONS
  Olmesartan may play a beneficial role in protecting lung in CHF by up-regulating AR and decreasing levels of PRA and Ang II.
authors.affiliation: Department of Emergency, Beijing Anzhen Hospital, Capital Medical University, China Beijing Institute of Heart Lung and Blood Vessel Diseases, China jiangzhilitg@sohu.com.
authors.forename: Y F
authors.initials: YF
authors.lastname: Li
authors.affiliation: Department of Emergency, Beijing Anzhen Hospital, Capital Medical University, China Beijing Institute of Heart Lung and Blood Vessel Diseases, China.
authors.forename: Z L
authors.initials: ZL
authors.lastname: Jiang
authors.affiliation: Department of Cardiology, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China.
authors.forename: F F
authors.initials: FF
authors.lastname: Cao
authors.affiliation: Department of Emergency, Beijing Anzhen Hospital, Capital Medical University, China Beijing Institute of Heart Lung and Blood Vessel Diseases, China.
authors.forename: F
authors.initials: F
authors.lastname: Liu
mesh_terms: D000804:Angiotensin II / Q000097:blood; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D007093:Imidazoles / Q000627:therapeutic use*; D008168:Lung / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D011941:Receptors, Adrenergic / Q000096:biosynthesis*; D012083:Renin / Q000097:blood; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D012333:RNA, Messenger; D011941:Receptors, Adrenergic; D013777:Tetrazoles; D000804:Angiotensin II; C437965:olmesartan; D012083:Renin
keywords: Adrenoceptor; angiotensin II; heart failure; lung; olmesartan